Private Microcaps Investors Group

#4. NNVC Potential Catalyst - NNVCReceives Approval As Proposed Phase II Clinical Trial Is Cleared For Further Regulatory Filing. Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo SHELTON, CT / ACCESS Newswire / May 8, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company") today reported that it has received approval from the National Ethics Committee for Health (CNES) of the Ministry of Public Health (MSP), of the Democratic Republic of Congo (DRC).  With this CNES approval, the proposed Phase II clinical trial to evaluate safety and effectiveness of NV-387 for the treatment of patients with M-P-o-x disease caused by hMPXV infection is cleared for further regulatory filing of a complete Clinical Trial Application ("CTA"). "We are now fully engaged in completing the detailed CTA for the Phase II human clinical trial of NV-387 for the treatment of M-P-O-X disease (hMPXV infection) for submission to the DRC Regulatory Agency, namely MSP," said Anil R. Diwan, PhD, President and Executive Chairman of the Company.

#3. NNVC Potential Catalyst - NNVC Is Working On A Potential Solution To A Major Global Threat. Measles Cases Are Increasing Globally; M-P-o-x Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution NanoViricides Explains Its Drug Strategy for Combating Viral Infections and Pand-emics SHELTON, CT / ACCESS Newswire / May 14, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that vi-rus-es cannot escape, explains its drug development strategy to combat important global viral threats. Measles outbreaks have continued to expand in the US, and the dramatic ten-fold increase in annual Measles cases in Europe last year indicates that Measles will be here to stay. Measles vac-cine failure cases have also been increasing according to the European data, which is an important cause for concern. Vac-cination rates are falling in developed countries. In this global scenario, NV-387, the clinical stage broad-spectrum, host-mimetic antiviral nanomedicine drug could perhaps be the only currently available drug candidate to combat the Measles vi-rus and disease. There is no approved drug for Measles vi-rus infection. The Company has already initiated the process for conducting an animal efficacy study that would provide an answer to how effective NV-387 would be against Measles vi-rus. The Company will make NV-387 available to any licensed physicians intending to treat Measles cases under the Individual Patient Expanded Access protocol of the US FDA. The Company has its own cGMP manufacturing facility. ... "NV-387 is a revolutionary antiviral drug that can combat many viral infections," said Anil R. Diwan, PhD, President and Executive Chairman of the Company. "We are advancing it rapidly towards establishing human clinical effectiveness data and regulatory approvals. We believe our M-P-o-x and Measles work will enable rapid advancement of the drug, and make a great global impact in large markets fulfilling unmet medical needs." ...

#2. NNVC Potential Catalyst - Bullish Technicals Are Triggered Across The Short, Medium, And Long Term! On Tuesday at 4:00PM EST, Barchart was reporting several triggered technical indicators across the short, medium, and long term for NNVC. Here's their list (as of 4:00PM EST Tuesday): Short Term Indicators 20 Day Moving Average 20 - 50 Day MA Crossover 20 - 100 Day MA Crossover 20 - 200 Day MA Crossover Medium Term Indicators 50 Day Moving Average 50 - 100 Day MA Crossover Long Term Indicators 100 Day Moving Average 150 Day Moving Average 200 Day Moving Average The website also shares its all-important "Trend Seeker" composite indicator is triggered as well. Make sure to watch these technical indicators closely moving forward.

#1. NNVC Potential Catalyst - A Low Float Could Create An Environment For Heightened Volatility Potential. According to info from the Yahoo Finance website, NNVC has a relatively low float. The website reports this profile to have roughly 15.49Mn shares in its float. Why is that important? It's important on one crucial level. Volatility potential. If positive company news appears in the midway part of 2025, could it provide a breakout spark?

Get ready for more info coming 🔥

#4. NNVC Receives Approval As Proposed Phase II Clinical Trial Is Cleared For Further Regulatory Filing

#3. NNVC Is Working On A Potential Solution To A Major Global Threat.

#2. Bullish Technicals Are Triggered Across The Short, Medium, And Long Term!

#1. A Low Float Could Create An Environment For Heightened Volatility Potential.

Here are 5 reasons why you don’t want to miss it

$NNVC

I’ve got a new great opportunity for you all today

Good morning guys

5. Commitment to Sustainability and ESG Goals SemiCab’s AI-driven optimization not only enhances operational efficiency but also contributes to environmental sustainability by reducing empty miles and associated carbon emissions. This aligns with global ESG initiatives, potentially attracting environmentally conscious investors and clients .

The company’s leadership includes industry veterans like CEO Gary Atkinson and Ajesh Kapoor, founder of SemiCab, who brings over 30 years of experience in supply chain and logistics technology. Their combined expertise is instrumental in steering Algorhythm’s strategic direction and technological advancements .

SemiCab’s platform seamlessly integrates with existing Transport Management Systems (TMS) and Electronic Logging Devices (ELD), facilitating real-time data exchange and automation. This compatibility reduces implementation barriers for clients, promoting quicker adoption and operational efficiency .

SemiCab initiated a pilot program with the world’s sixth-largest consumer packaged goods company in southwestern India. This engagement not only validates SemiCab’s AI-powered platform but also opens avenues for scaling operations with major multinational clients, enhancing revenue prospects .